Research ExplorerPublicationsComparable outcomes of haploidentical transplant with TBF co...

Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia

Standard

Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. / Bazarbachi, Ali; Labopin, Myriam; Blaise, Didier; Forcade, Edouard; Socié, Gerard; Berceanu, Ana; Angelucci, Emanuele; Bulabois, Claude Eric; Kröger, Nicolaus; Rambaldi, Alessandro; Ceballos, Patrice; Mielke, Stephan; El Cheikh, Jean; Yakoub-Agha, Ibrahim; Savani, Bipin; Spyridonidis, Alexandros; Nagler, Arnon; Mohty, Mohamad.

In: BONE MARROW TRANSPL, Vol. 56, No. 3, 03.2021, p. 622-634.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bazarbachi, A, Labopin, M, Blaise, D, Forcade, E, Socié, G, Berceanu, A, Angelucci, E, Bulabois, CE, Kröger, N, Rambaldi, A, Ceballos, P, Mielke, S, El Cheikh, J, Yakoub-Agha, I, Savani, B, Spyridonidis, A, Nagler, A & Mohty, M 2021, 'Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia', BONE MARROW TRANSPL, vol. 56, no. 3, pp. 622-634. https://doi.org/10.1038/s41409-020-01074-z

APA

Bazarbachi, A., Labopin, M., Blaise, D., Forcade, E., Socié, G., Berceanu, A., Angelucci, E., Bulabois, C. E., Kröger, N., Rambaldi, A., Ceballos, P., Mielke, S., El Cheikh, J., Yakoub-Agha, I., Savani, B., Spyridonidis, A., Nagler, A., & Mohty, M. (2021). Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. BONE MARROW TRANSPL, 56(3), 622-634. https://doi.org/10.1038/s41409-020-01074-z

Vancouver

Bazarbachi A, Labopin M, Blaise D, Forcade E, Socié G, Berceanu A et al. Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. BONE MARROW TRANSPL. 2021 Mar;56(3):622-634. https://doi.org/10.1038/s41409-020-01074-z

Bibtex

@article{794d25eb41d9495cb5505bdb07469282,
title = "Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia",
abstract = "We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant cyclophosphamide (ptCy), to 2083 patients receiving matched unrelated donor (MUD) transplantation using fludarabine/busulfan (FB) conditioning and in vivo T-cell depletion. For intermediate cytogenetic risk AML transplanted in first complete remission (CR1), multivariate analysis revealed that haplo-TBF significantly increased nonrelapse mortality (NRM) (HR 2.1; p = 0.0006) but did not affect relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS), or graft-versus-host disease-free, relapse-free survival (GRFS). For high cytogenetic risk AML transplanted in CR1, haplo-TBF significantly increased NRM (HR = 2.7; p = 0.02), decreased RI (HR = 0.45; p = 0.03) but had no influence on LFS, OS, or GRFS. For AML transplanted in CR2, haplo-TBF significantly increased NRM (HR = 2.36; p = 0.008), decreased RI (HR = 0.38; p = 0.005), but had no influence on LFS, OS, or GRFS. Finally, for AML patients transplanted with active disease, haplo-TBF had no influence on transplant outcomes. In conclusion, compared to MUD-FB, haplo-TBF increased NRM, reduced RI in high-risk AML in CR, resulting in similar LFS, OS, and GRFS. These results comparing two different approaches support the use of a haploidentical family donor for high-risk AML patients lacking a matched sibling donor.",
author = "Ali Bazarbachi and Myriam Labopin and Didier Blaise and Edouard Forcade and Gerard Soci{\'e} and Ana Berceanu and Emanuele Angelucci and Bulabois, {Claude Eric} and Nicolaus Kr{\"o}ger and Alessandro Rambaldi and Patrice Ceballos and Stephan Mielke and {El Cheikh}, Jean and Ibrahim Yakoub-Agha and Bipin Savani and Alexandros Spyridonidis and Arnon Nagler and Mohamad Mohty",
year = "2021",
month = mar,
doi = "10.1038/s41409-020-01074-z",
language = "English",
volume = "56",
pages = "622--634",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia

AU - Bazarbachi, Ali

AU - Labopin, Myriam

AU - Blaise, Didier

AU - Forcade, Edouard

AU - Socié, Gerard

AU - Berceanu, Ana

AU - Angelucci, Emanuele

AU - Bulabois, Claude Eric

AU - Kröger, Nicolaus

AU - Rambaldi, Alessandro

AU - Ceballos, Patrice

AU - Mielke, Stephan

AU - El Cheikh, Jean

AU - Yakoub-Agha, Ibrahim

AU - Savani, Bipin

AU - Spyridonidis, Alexandros

AU - Nagler, Arnon

AU - Mohty, Mohamad

PY - 2021/3

Y1 - 2021/3

N2 - We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant cyclophosphamide (ptCy), to 2083 patients receiving matched unrelated donor (MUD) transplantation using fludarabine/busulfan (FB) conditioning and in vivo T-cell depletion. For intermediate cytogenetic risk AML transplanted in first complete remission (CR1), multivariate analysis revealed that haplo-TBF significantly increased nonrelapse mortality (NRM) (HR 2.1; p = 0.0006) but did not affect relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS), or graft-versus-host disease-free, relapse-free survival (GRFS). For high cytogenetic risk AML transplanted in CR1, haplo-TBF significantly increased NRM (HR = 2.7; p = 0.02), decreased RI (HR = 0.45; p = 0.03) but had no influence on LFS, OS, or GRFS. For AML transplanted in CR2, haplo-TBF significantly increased NRM (HR = 2.36; p = 0.008), decreased RI (HR = 0.38; p = 0.005), but had no influence on LFS, OS, or GRFS. Finally, for AML patients transplanted with active disease, haplo-TBF had no influence on transplant outcomes. In conclusion, compared to MUD-FB, haplo-TBF increased NRM, reduced RI in high-risk AML in CR, resulting in similar LFS, OS, and GRFS. These results comparing two different approaches support the use of a haploidentical family donor for high-risk AML patients lacking a matched sibling donor.

AB - We compared transplant outcomes of 708 acute myeloid leukemia (AML) patients receiving haploidentical allogeneic hematopoietic-cell transplantation using thiotepa/busulfan/fludarabine (TBF) conditioning with posttransplant cyclophosphamide (ptCy), to 2083 patients receiving matched unrelated donor (MUD) transplantation using fludarabine/busulfan (FB) conditioning and in vivo T-cell depletion. For intermediate cytogenetic risk AML transplanted in first complete remission (CR1), multivariate analysis revealed that haplo-TBF significantly increased nonrelapse mortality (NRM) (HR 2.1; p = 0.0006) but did not affect relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS), or graft-versus-host disease-free, relapse-free survival (GRFS). For high cytogenetic risk AML transplanted in CR1, haplo-TBF significantly increased NRM (HR = 2.7; p = 0.02), decreased RI (HR = 0.45; p = 0.03) but had no influence on LFS, OS, or GRFS. For AML transplanted in CR2, haplo-TBF significantly increased NRM (HR = 2.36; p = 0.008), decreased RI (HR = 0.38; p = 0.005), but had no influence on LFS, OS, or GRFS. Finally, for AML patients transplanted with active disease, haplo-TBF had no influence on transplant outcomes. In conclusion, compared to MUD-FB, haplo-TBF increased NRM, reduced RI in high-risk AML in CR, resulting in similar LFS, OS, and GRFS. These results comparing two different approaches support the use of a haploidentical family donor for high-risk AML patients lacking a matched sibling donor.

U2 - 10.1038/s41409-020-01074-z

DO - 10.1038/s41409-020-01074-z

M3 - SCORING: Journal article

C2 - 33020591

VL - 56

SP - 622

EP - 634

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 3

ER -